Beijing Gobroad Boren Pharmaceutical

GoBroad Healthcare Group is a leading research-oriented medical group in China, specializing in hematology, oncology, and neuroscience. Founded in 2017 and backed by Hillhouse Capital, the group operates a network of specialized hospitals, including the flagship Beijing GoBroad Boren Hospital. It is a global leader in cellular immunotherapy, particularly CAR-T cell therapy, having completed over 4,000 clinical research cases with high remission rates. GoBroad functions as an Academic Research Organization (ARO), integrating clinical treatment, precision diagnostics, and translational research to accelerate the development of innovative therapies for complex and refractory diseases. The group's extensive research infrastructure supports a robust pipeline of CAR-T programs targeting antigens such as CD19, CD22, CD7, and BCMA, positioning it at the forefront of hematologic malignancy treatment.